Kyverna Therapeutics Reports Positive Clinical Milestones, Secures Funding for Runway into 2028, and Remediates Internal Control Weaknesses

summarizeSummary

This 10-K provides a comprehensive update on Kyverna Therapeutics' operations and financial health. The company reported an increased net loss for 2025 but highlighted a strong cash position of $279.3 million, which management projects will fund operations into 2028. This financial stability is bolstered by successful capital raises in 2025, including $16.4 million from an ATM facility, $98.7 million from an underwritten public offering, and a $25.0 million term loan. Operationally, the company achieved critical milestones with positive Phase 2 results for its lead candidate miv-cel in Stiff Person Syndrome (SPS), with a BLA submission planned for H1 2026, and the initiation of a Phase 3 trial for generalized Myasthenia Gravis (gMG). The acceptance of an IND for KYV-102 further expands its pipeline. Additionally, the company successfully remediated previously identified material weaknesses in internal control over financial reporting and saw a shareholder class action lawsuit dismissed, indicating improved corporate governance and reduced legal risk. Investors should note the ongoing need for capital and the dilutive nature of recent offerings, as well as the industry-wide FDA investigation into CAR T-cell malignancy risk, which could impact future regulatory approvals.

check_boxKey Events

• Strong Financial Position and Runway

  The company reported $279.3 million in cash, cash equivalents, and available-for-sale marketable securities as of December 31, 2025, which management estimates will fund operations into 2028.

• Successful Capital Raises in 2025

  Kyverna raised $140.6 million in net proceeds during 2025 through an At-The-Market (ATM) facility, an underwritten public offering, and a $25.0 million term loan facility.

• Positive Clinical Progress for miv-cel (KYV-101)

  The company completed a registrational Phase 2 trial (KYSA-8) for Stiff Person Syndrome (SPS) with positive topline results and plans to submit a Biologics License Application (BLA) to the FDA in the first half of 2026. It also initiated a Phase 3 registrational trial for generalized Myasthenia Gravis (gMG) in late 2025, following positive interim Phase 2 data.

• Pipeline Advancement with KYV-102

  The Investigational New Drug (IND) application for KYV-102, a proprietary whole blood, rapid manufacturing process CAR T-cell product candidate, was accepted by the U.S. FDA in January 2026.

auto_awesomeAnalysis

This 10-K provides a comprehensive update on Kyverna Therapeutics' operations and financial health. The company reported an increased net loss for 2025 but highlighted a strong cash position of $279.3 million, which management projects will fund operations into 2028. This financial stability is bolstered by successful capital raises in 2025, including $16.4 million from an ATM facility, $98.7 million from an underwritten public offering, and a $25.0 million term loan. Operationally, the company achieved critical milestones with positive Phase 2 results for its lead candidate miv-cel in Stiff Person Syndrome (SPS), with a BLA submission planned for H1 2026, and the initiation of a Phase 3 trial for generalized Myasthenia Gravis (gMG). The acceptance of an IND for KYV-102 further expands its pipeline. Additionally, the company successfully remediated previously identified material weaknesses in internal control over financial reporting and saw a shareholder class action lawsuit dismissed, indicating improved corporate governance and reduced legal risk. Investors should note the ongoing need for capital and the dilutive nature of recent offerings, as well as the industry-wide FDA investigation into CAR T-cell malignancy risk, which could impact future regulatory approvals.